
CLM-5, Mouse, clone TX69
HM1147 (clone TX69) is a monoclonal antibody against mouse CLM-5.This molecule, also known as MAIR-IV, LMIR4 or CD300ld1, is a member of the myeloid-associated immunoglobulin-like receptor family (MAIR, CD300). The CD300 family of receptors is an evolutionary conserved receptor family that belongs to the Ig superfamily and is expressed predominantly by the myeloid lineage. In mice, nine members have been reported with different nomenclature systems, such as myeloid-associated Ig-like receptor (MAIR), leukocyte mono-Ig-like receptor (LMIR), DC-derived Ig-like receptor (DIgR), and CMRF-35-like molecule (CLM). CD300 molecules act as either activating or inhibitory receptors through interactions with adaptor molecules, such as PAD12, DAP10, and FcRγ. CLM-5 is preferentially expressed on Gr-1+/Mac-1+ neutrophils in the peripheral blood, bone marrow, peritoneal cavity, and spleen. It is also found on Mac-1+/Gr-1+ macrophages and CD11c+ dendritic cells. Its expression is regulated by TLR ligands LPS and flagellin. In association with the immunoreceptor tyrosine based activating motif (ITAM)-bearing adaptor FcRγ, CLM-5 mediates activation signals for neutrophils thereby playing an important role for innate immunity such as the induction of proinflammatory cytokines TNF-a and IL-6.
• W: Western blot was performed under reduced conditions. The expected band size is 35 kDa.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA